Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Paul Richardson
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Anatomy
Procedures
Physiology
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
57
Anderson, Kenneth
53
Hideshima, Teru
43
Chauhan, Dharminder
28
Munshi, Nikhil
28
podar, klaus
22
Schlossman, Robert
20
Mitsiades, Constantine
17
Tai, Yu-Tzu
13
Raje, Noopur
11
Mitsiades, Nicholas
11
Akiyama, Masaharu
11
Hayashi, Toshiaki
10
Elias, A
10
Frei, Emil
10
Catley, Laurence
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Paul Richardson (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Chauhan Dharminder; Singh Ajita V; Brahmandam Mohan; Carrasco Ruben; Bandi Madhavi; Hideshima Teru; Bianchi Giada; Podar Klaus; Tai Yu-Tzu; Mitsiades Constantine; Raje Noopur; Jaye David L; Kumar Shaji K; Richardson Paul; Munshi Nikhil; Anderson Kenneth C
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Cancer cell 2009;16(4):309-23.
-
2009: Richardson Paul; Jagannath Sundar; Hussein Mohamad; Berenson James; Singhal Seema; Irwin David; Williams Stephanie F; Bensinger William; Badros Ashraf Z; Vescio Robert; Kenvin Laurie; Yu Zhinuan; Olesnyckyj Marta; Zeldis Jerome; Knight Robert; Anderson Kenneth C
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Blood 2009;114(4):772-8.
-
2008: Cutler Corey; Stevenson Kristen; Kim Haesook T; Richardson Paul; Ho Vincent T; Linden Erica; Revta Carolyn; Ebert Ruth; Warren Diane; Choi Sung; Koreth John; Armand Philippe; Alyea Edwin; Carter Shelly; Horowitz Mary; Antin Joseph H; Soiffer Robert
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
Blood 2008;112(12):4425-31.
-
2008: Lacy Martha Q; Alsina Melissa; Fonseca Rafael; Paccagnella M Luisa; Melvin Carrie L; Yin Donghua; Sharma Amarnath; Enriquez Sarano M; Pollak Michael; Jagannath Sundar; Richardson Paul; Gualberto Antonio
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(19):3196-203.
-
2008: Richardson Paul; Mitsiades Constantine; Colson Kathleen; Reilly Eileen; McBride Laura; Chiao Judy; Sun Linda; Ricker Justin; Rizvi Syed; Oerth Carol; Atkins Barbara; Fearen Ivy; Anderson Kenneth; Siegel David
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
Leukemia & lymphoma 2008;49(3):502-7.
-
2008: Chauhan Dharminder; Singh Ajita; Brahmandam Mohan; Podar Klaus; Hideshima Teru; Richardson Paul; Munshi Nikhil; Palladino Michael A; Anderson Kenneth C
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Blood 2008;111(3):1654-64.
-
2008: Anderson K C; Kyle R A; Rajkumar S V; Stewart A K; Weber D; Richardson P;
Clinically relevant end points and new drug approvals for myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(2):231-9.
-
2007: Tai Yu-Tzu; Fulciniti Mariateresa; Hideshima Teru; Song Weihua; Leiba Merav; Li Xian-Feng; Rumizen Matthew; Burger Peter; Morrison Aileen; Podar Klaus; Chauhan Dharminder; Tassone Pierfrancesco; Richardson Paul; Munshi Nikhil C; Ghobrial Irene M; Anderson Kenneth C
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Blood 2007;110(5):1656-63.
-
2007: Younes Hashem; Leleu Xavier; Hatjiharissi Evdoxia; Moreau Anne-Sophie; Hideshima Teru; Richardson Paul; Anderson Kenneth C; Ghobrial Irene M
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3771-5.
-
2007: Ghobrial Joanne; Ghobrial Irene M; Mitsiades Constantine; Leleu Xavier; Hatjiharissi Evdoxia; Moreau Anne-Sophie; Roccaro Aldo; Schlossman Robert; Hideshima Teru; Anderson Kenneth C; Richardson Paul
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Oncology (Williston Park, N.Y.) 2007;21(7):785-92; discussion 798-800.
-
2007: Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson K C
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Oncogene 2007;26(16):2374-80.
-
2007: Ghobrial Irene M; Leleu Xavier; Hatjiharissi Evdoxia; Hideshima Teru; Mitsiades Constantine; Schlossman Robert; Anderson Kenneth C; Richardson Paul
Emerging drugs in multiple myeloma.
Expert opinion on emerging drugs 2007;12(1):155-63.
-
2007: Chauhan Dharminder; Neri Paola; Velankar Mugdha; Podar Klaus; Hideshima Teru; Fulciniti Mariateresa; Tassone Pierfrancesco; Raje Noopur; Mitsiades Constantine; Mitsiades Nicholas; Richardson Paul; Zawel Leigh; Tran Mary; Munshi Nikhil; Anderson Kenneth C
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Blood 2007;109(3):1220-7.
-
2006: Hideshima Teru; Neri Paola; Tassone Pierfranchesco; Yasui Hiroshi; Ishitsuka Kenji; Raje Noopur; Chauhan Dharminder; Podar Klaus; Mitsiades Constantine; Dang Lenny; Munshi Nikhil; Richardson Paul; Schenkein David; Anderson Kenneth C
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5887-94.
-
2006: Tai Yu-Tzu; Li Xian-Feng; Breitkreutz Iris; Song Weihua; Neri Paola; Catley Laurence; Podar Klaus; Hideshima Teru; Chauhan Dharminder; Raje Noopur; Schlossman Robert; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2006;66(13):6675-82.
-
2006: Richardson Paul
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Clinical advances in hematology & oncology : H&O 2006;4(5):4-5; discussion 8; suppl 13.
-
2006: Richardson Paul; Jagannath Sundar; Colson Kathleen
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Clinical advances in hematology & oncology : H&O 2006;4(5):1; discussion 8; suppl 13.
-
2006: Kumar Shaji; Raje Noopur; Hideshima Teru; Ishitsuka Kenji; Podar Klaus; Le Gouille Steven; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.
British journal of haematology 2006;132(6):698-704.
-
2005: Tai Yu-Tzu; Li Xian-Feng; Catley Laurence; Coffey Rory; Breitkreutz Iris; Bae Jooeun; Song Weihua; Podar Klaus; Hideshima Teru; Chauhan Dharminder; Schlossman Robert; Richardson Paul; Treon Steven P; Grewal Iqbal S; Munshi Nikhil C; Anderson Kenneth C
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Cancer research 2005;65(24):11712-20.
-
2005: Chauhan Dharminder; Catley Laurence; Li Guilan; Podar Klaus; Hideshima Teru; Velankar Mugdha; Mitsiades Constantine; Mitsiades Nicolas; Yasui Hiroshi; Letai Anthony; Ovaa Huib; Berkers Celia; Nicholson Benjamin; Chao Ta-Hsiang; Neuteboom Saskia T C; Richardson Paul; Palladino Michael A; Anderson Kenneth C
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Cancer cell 2005;8(5):407-19.
-
2005: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Neri Paola; He Deli; Mitsiades Nicholas; Richardson Paul; Chang Yan; Schindler Joanne; Carver Bradley; Anderson Kenneth C
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Cancer research 2005;65(18):8350-8.
-
2005: Hideshima Teru; Chauhan Dharminder; Richardson Paul; Anderson Kenneth C
Identification and validation of novel therapeutic targets for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6345-50.
-
2005: Ishitsuka Kenji; Hideshima Teru; Hamasaki Makoto; Raje Noopur; Kumar Shaji; Hideshima Hiromasa; Shiraishi Norihiko; Yasui Hiroshi; Roccaro Aldo M; Richardson Paul; Podar Klaus; Le Gouill Steven; Chauhan Dharminder; Tamura Kazuo; Arbiser Jack; Anderson Kenneth C
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
Blood 2005;106(5):1794-800.
-
2005: Tai Yu-Tzu; Li Xianfeng; Tong Xia; Santos Daniel; Otsuki Takemi; Catley Laurence; Tournilhac Olivier; Podar Klaus; Hideshima Teru; Schlossman Robert; Richardson Paul; Munshi Nikhil C; Luqman Mohammad; Anderson Kenneth C
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Cancer research 2005;65(13):5898-906.
-
2005: Kumar S; Raje N; Hideshima T; Ishitsuka K; Roccaro A; Shiraishi N; Hamasaki M; Yasui H; Munshi N C; Richardson P; Figg W D; Anderson K C
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(7):1253-61.
-
2005: Hideshima Teru; Bradner James E; Wong Jason; Chauhan Dharminder; Richardson Paul; Schreiber Stuart L; Anderson Kenneth C
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(24):8567-72.
-
2005: Richardson Paul
New therapies for the treatment of multiple myeloma.
Clinical advances in hematology & oncology : H&O 2005;3(5):345-6.
-
2005: Chauhan Dharminder; Hideshima Teru; Mitsiades Constantine; Richardson Paul; Anderson Kenneth C
Proteasome inhibitor therapy in multiple myeloma.
Molecular cancer therapeutics 2005;4(4):686-92.
-
2004: Catley Laurence; Tai Yu-Tzu; Shringarpure Reshma; Burger Renate; Son Moni Thi; Podar Klaus; Tassone Pierfrancesco; Chauhan Dharminder; Hideshima Teru; Denis Louis; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Cancer research 2004;64(23):8746-53.
-
2004: Raje Noopur; Kumar Shaji; Hideshima Teru; Ishitsuka Kenji; Chauhan Dharminder; Mitsiades Constantine; Podar Klaus; Le Gouill Steven; Richardson Paul; Munshi Nikhil C; Stirling David I; Antin Joseph H; Anderson Kenneth C
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Blood 2004;104(13):4188-93.
-
2004: Hayashi Toshiaki; Hideshima Teru; Nguyen Aaron N; Munoz Olivier; Podar Klaus; Hamasaki Makoto; Ishitsuka Kenji; Yasui Hiroshi; Richardson Paul; Chakravarty Sarvajit; Murphy Alison; Chauhan Dharminder; Higgins Linda S; Anderson Kenneth C
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7540-6.
-
2004: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Mitsiades Constantine; Schlossman Robert; Munshi Nikhil; Richardson Paul; Cotter Finbarr E; Anderson Kenneth C
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Blood 2004;104(8):2458-66.
-
2004: Thornley Ian; Lehmann Leslie E; Sung Lillian; Holmes Colleen; Spear Jan M; Brennan Lisa; Vangel Mark; Bechard Lori J; Richardson Paul; Duggan Christopher; Guinan Eva C
A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2004;10(9):635-44.
-
2004: Richardson Paul; Schlossman Robert; Jagannath Sundar; Alsina Melissa; Desikan Raman; Blood Emily; Weller Edie; Mitsiades Constantine; Hideshima Teru; Davies Faith; Doss Deborah; Freeman Andrea; Bosch Joan; Patin John; Knight Robert; Zeldis Jerome; Dalton William; Anderson Kenneth
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):875-82.
-
2004: Richardson Paul; Hideshima Teru; Anderson Kenneth C
An update of novel therapeutic approaches for multiple myeloma.
Current treatment options in oncology 2004;5(3):227-38.
-
2004: Raje Noopur; Hideshima Teru; Davies Faith E; Chauhan Dharminder; Treon Steven P; Young Gloria; Tai Yu-Tzu; Avigan David; Gong Jianlin; Schlossman Robert L; Richardson Paul; Kufe Donald W; Anderson Kenneth C
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
British journal of haematology 2004;125(3):343-52.
-
2004: Tai Yu-Tzu; Catley Laurence P; Mitsiades Constantine S; Burger Renate; Podar Klaus; Shringpaure Reshma; Hideshima Teru; Chauhan Dharminder; Hamasaki Makoto; Ishitsuka Kenji; Richardson Paul; Treon Steven P; Munshi Nikhil C; Anderson Kenneth C
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Cancer research 2004;64(8):2846-52.
-
2004: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Shringarpure Reshma; Catley Laurence; Mitsiades Constantine; Munshi Nikhil; Tai Yu Tzu; Suh Nanjoo; Gribble Gordon W; Honda Tadashi; Schlossman Robert; Richardson Paul; Sporn Michael B; Anderson Kenneth C
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Blood 2004;103(8):3158-66.
-
2003: Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson K C
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Bone marrow transplantation 2003;32(12):1145-51.
-
2003: Hideshima Teru; Hayashi Toshiaki; Chauhan Dharminder; Akiyama Masaharu; Richardson Paul; Anderson Kenneth
Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines.
Oncogene 2003;22(54):8797-801.
-
2003: Akiyama Masaharu; Hideshima Teru; Shammas Masood A; Hayashi Toshiaki; Hamasaki Makoto; Tai Yu-Tzu; Richardson Paul; Gryaznov Sergei; Munshi Nikhil C; Anderson Kenneth C
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
Cancer research 2003;63(19):6187-94.
-
2003: Catley Laurence; Weisberg Ellen; Tai Yu-Tzu; Atadja Peter; Remiszewski Stacy; Hideshima Teru; Mitsiades Nicholas; Shringarpure Reshma; LeBlanc Richard; Chauhan Dharminder; Munshi Nikhil C; Schlossman Robert; Richardson Paul; Griffin James; Anderson Kenneth C
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Blood 2003;102(7):2615-22.
-
2003: Tai Yu-Tzu; Podar Klaus; Catley Laurence; Tseng Yu-Hua; Akiyama Masaharu; Shringarpure Reshma; Burger Renate; Hideshima Teru; Chauhan Dharminder; Mitsiades Nicholas; Richardson Paul; Munshi Nikhil C; Kahn C Ronald; Mitsiades Constantine; Anderson Kenneth C
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.
Cancer research 2003;63(18):5850-8.
-
2003: Richardson Paul
Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation.
Oncology (Williston Park, N.Y.) 2003;17(8):1063-5.
-
2003: Hideshima Teru; Richardson Paul; Anderson Kenneth C
Novel therapeutic approaches for multiple myeloma.
Immunological reviews 2003;194():164-76.
-
2003: Hayashi Toshiaki; Hideshima Teru; Akiyama Masaharu; Raje Noopur; Richardson Paul; Chauhan Dharminder; Anderson Kenneth C
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.
Blood 2003;102(4):1435-42.
-
2003: Hayashi Toshiaki; Treon Steven P; Hideshima Teru; Tai Yu-Tzu; Akiyama Masaharu; Richardson Paul; Chauhan Dharminder; Grewal Iqbal S; Anderson Kenneth C
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.
British journal of haematology 2003;121(4):592-6.
-
2003: Richardson Paul
Clinical update: proteasome inhibitors in hematologic malignancies.
Cancer treatment reviews 2003;29 Suppl 1():33-9.
-
2003: Chauhan Dharminder; Li Guilan; Auclair Daniel; Hideshima Teru; Richardson Paul; Podar Klaus; Mitsiades Nicholas; Mitsiades Constantine; Li Cheng; Kim Ryung Suk; Munshi Nikhil; Chen Lan Bo; Wong Wing; Anderson Kenneth C
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
Blood 2003;101(9):3606-14.
-
2003: Hideshima Teru; Mitsiades Constantine; Akiyama Masaharu; Hayashi Toshiaki; Chauhan Dharminder; Richardson Paul; Schlossman Robert; Podar Klaus; Munshi Nikhil C; Mitsiades Nicholas; Anderson Kenneth C
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Blood 2003;101(4):1530-4.
-
2003: Akiyama Masaharu; Hideshima Teru; Hayashi Toshiaki; Tai Yu-Tzu; Mitsiades Constantine S; Mitsiades Nicholas; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
Cancer research 2003;63(1):18-21.
-
2003: Hideshima Teru; Akiyama Masaharu; Hayashi Toshiaki; Richardson Paul; Schlossman Robert; Chauhan Dharminder; Anderson Kenneth C
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.
Blood 2003;101(2):703-5.
-
2003: Richardson Paul
Hemostatic complications of hematopoietic stem cell transplantation: from hemorrhage to microangiopathies and VOD.
Pathophysiology of haemostasis and thrombosis 2003;33 Suppl 1():50-3.
-
2002: Chauhan Dharminder; Catley Laurence; Hideshima Teru; Li Guilan; Leblanc Richard; Gupta Deepak; Sattler Martin; Richardson Paul; Schlossman Robert L; Podar Klaus; Weller Edie; Munshi Nikhil; Anderson Kenneth C
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
Blood 2002;100(6):2187-94.
-
2002: Hayashi Toshiaki; Hideshima Teru; Akiyama Masaharu; Richardson Paul; Schlossman Robert L; Chauhan Dharminder; Munshi Nikhil C; Waxman Samuel; Anderson Kenneth C
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
Molecular cancer therapeutics 2002;1(10):851-60.
-
2002: Akiyama Masaharu; Hideshima Teru; Hayashi Toshiaki; Tai Yu-Tzu; Mitsiades Constantine S; Mitsiades Nicholas; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Cytokines modulate telomerase activity in a human multiple myeloma cell line.
Cancer research 2002;62(13):3876-82.
-
2002: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Podar Klaus; Akiyama Masaharu; Gupta Deepak; Richardson Paul; Munshi Nikhil; Anderson Kenneth C
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
Molecular cancer therapeutics 2002;1(7):539-44.
-
2002: Hideshima Teru; Chauhan Dharminder; Richardson Paul; Mitsiades Constantine; Mitsiades Nicholas; Hayashi Toshiaki; Munshi Nikhil; Dang Lenny; Castro Alfredo; Palombella Vito; Adams Julian; Anderson Kenneth C
NF-kappa B as a therapeutic target in multiple myeloma.
The Journal of biological chemistry 2002;277(19):16639-47.
-
2002: Chauhan Dharminder; Auclair Daniel; Robinson Elisabeth K; Hideshima Teru; Li Guilan; Podar Klaus; Gupta Deepak; Richardson Paul; Schlossman Robert L; Krett Nancy; Chen Lan Bo; Munshi Nikhil C; Anderson Kenneth C
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
Oncogene 2002;21(9):1346-58.
-
2002: Elias Anthony D; Skarin Arthur T; Richardson Paul; Ibrahim Joseph; McCauley Mary; Frei Emil
Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002;8(6):326-33.
-
2002: Elias A D; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002;8(4):198-205.
-
2001: Gupta D; Treon S P; Shima Y; Hideshima T; Podar K; Tai Y T; Lin B; Lentzsch S; Davies F E; Chauhan D; Schlossman R L; Richardson P; Ralph P; Wu L; Payvandi F; Muller G; Stirling D I; Anderson K C
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(12):1950-61.
-
2001: Hideshima T; Chauhan D; Podar K; Schlossman R L; Richardson P; Anderson K C
Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Seminars in oncology 2001;28(6):607-12.
-
2001: Elias A D; Richardson P; Avigan D; Ibrahim J; Joyce R; McDermott D; Levine J; Warren D; McCauley M; Wheeler C; Frei E
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
Bone marrow transplantation 2001;28(5):447-54.
-
2001: Mitsiades C S; Treon S P; Mitsiades N; Shima Y; Richardson P; Schlossman R; Hideshima T; Anderson K C
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Blood 2001;98(3):795-804.
-
2001: Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson K C
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Oncogene 2001;20(33):4519-27.
-
2001: Podar K; Tai Y T; Davies F E; Lentzsch S; Sattler M; Hideshima T; Lin B K; Gupta D; Shima Y; Chauhan D; Mitsiades C; Raje N; Richardson P; Anderson K C
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Blood 2001;98(2):428-35.
-
2001: Hideshima T; Richardson P; Chauhan D; Palombella V J; Elliott P J; Adams J; Anderson K C
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Cancer research 2001;61(7):3071-6.
-
2001: Elias A D; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Bone marrow transplantation 2001;27(3):269-78.
-
2001: Richardson P; Guinan E
Hepatic veno-occlusive disease following hematopoietic stem cell transplantation.
Acta haematologica 2001;106(1-2):57-68.
-
2000: Hideshima T; Chauhan D; Shima Y; Raje N; Davies F E; Tai Y T; Treon S P; Lin B; Schlossman R L; Richardson P; Muller G; Stirling D I; Anderson K C
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Blood 2000;96(9):2943-50.
-
2000: Avigan D; Wu Z; Joyce R; Elias A; Richardson P; McDermott D; Levine J; Kennedy L; Giallombardo N; Hurley D; Gong J; Kufe D
Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer.
Bone marrow transplantation 2000;26(2):169-76.
-
2000: Kraeft S K; Sutherland R; Gravelin L; Hu G H; Ferland L H; Richardson P; Elias A; Chen L B
Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):434-42.
-
2000: Nieto Y; Champlin R E; Wingard J R; Vredenburgh J F; Elias A D; Richardson P; Glaspy J; Jones R B; Stiff P J; Bearman S I; Cagnoni P J; McSweeney P A; LeMaistre C F; Pecora A L; Shpall E F
Status of high-dose chemotherapy for breast cancer: a review.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2000;6(5):476-95.
-
2000: Frei E; Ara G; Teicher B; Bunnell C; Richardson P; Wheeler C; Tew K; Elias A
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Cancer chemotherapy and pharmacology 2000;45(3):239-46.
-
1999: Richardson P; Guinan E
The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches.
British journal of haematology 1999;107(3):485-93.
-
1999: Frei E; Richardson P; Avigan D; Bunnell C; Wheeler C; Elias A
The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.
Bone marrow transplantation 1999;24(9):939-45.
-
1999: Avigan D; Wu Z; Gong J; Joyce R; Levine J; Elias A; Richardson P; Milano J; Kennedy L; Anderson K; Kufe D
Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2735-41.
-
1999: Elias A; Ibrahim J; Skarin A T; Wheeler C; McCauley M; Ayash L; Richardson P; Schnipper L; Antman K H; Frei E
Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1175.
-
1998: Frei E; Elias A; Wheeler C; Richardson P; Hryniuk W
The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(9):2027-37.
-
1998: Avigan D; Richardson P; Elias A; Demetri G; Shapiro M; Schnipper L; Wheeler C
Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature.
Cancer 1998;83(3):409-14.
-
1998: Ayash L J; Elias A; Ibrahim J; Schwartz G; Wheeler C; Reich E; Lynch C; Warren D; Shapiro C; Richardson P; Hurd D; Schnipper L; Frei E; Antman K
High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1000-7.
-
1996: Ayash L J; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher B A; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(11):2984-92.
Sign-in to see more
